Recent animal studies have supported that Lactobacillus plantarum PS128 (PS128) can reduce the severity of anxiety and depression. However, previous studies did not focus on the sleep quality and mood of humans. This study determines whether PS128 reduces the severity of anxiety and depressive symptoms, regulates autonomic nervous system function, and improves sleep quality. Forty participants between 20 and 40 years of age with self-reported insomnia were randomly assigned to two groups, a PS128 group and a placebo group, in a double-blind trial. Participants took two capsules of either PS128 or a placebo after dinner for 30 days. Study measures included subjective depressive symptoms, anxiety and sleep questionnaires, and miniature-polysomnography recordings at baseline and on the 15th and 30th days of taking capsules. Overall, all outcomes were comparable between the two groups at baseline and within the 30-day period, yet some differences were still found. Compared to the control group, the PS128 group showed significant decreases in Beck Depression Inventory-II scores, fatigue levels, brainwave activity, and awakenings during the deep sleep stage. Their improved depressive symptoms were related to changes in brain waves and sleep maintenance. These findings suggest that daily administration of PS128 may lead to a decrease in depressive symptoms, fatigue level, cortical excitation, and an improvement in sleep quality during the deep sleep stage. Daily consumption of PS128 as a dietary supplement may improve the depressive symptoms and sleep quality of insomniacs, although further investigation is warranted.

To explore the role of autonomic nervous system in initiation of sleep-wake transitions. Changes in cardiovascular variability during sleep-wake transitions of adult male Wistar-Kyoto rats on their normal daytime sleep were analyzed. A 6-h daytime sleep-wakefulness recording session was performed. Electroencephalogram and electromyogram (EMG) signals were subjected to continuous power spectral analysis, from which mean power frequency of the electroencephalogram (MPF) and power of the EMG were quantified. Active waking (AW), quiet sleep (QS), and paradoxical sleep (PS) were defined every 8 s according to corresponding MPF and EMG power. Continuous power spectral analysis of R-R intervals was performed to quantify its high-frequency power (HF, 0.6–2.4 Hz), low-frequency power (0.06–0.6 Hz) to HF ratio (LF/HF). MPF exhibited two phases of change during AW-QS and QS-AW transitions: a slowly changing first phase followed by a rapidly changing second phase. HF increased linearly with the decrease of MPF during the first phase of AW-QS transition whereas LF/HF increased linearly with the increase of MPF during the first phase of QSAW transition. However, the LF/HF was not correlated with the HF. The MPF and HF exhibited only a rapidly changing phase during QS-PS transition. The LF/HF declined transiently during the QS-PS transition, followed by a sustained increase in PS. The parasympathetic activity before falling asleep and the sympathetic activity before waking up change coincidentally with EEG frequency, and may respectively contain the messages of sleeping and waking drives.